Inhibitory Effects of Novel AP-1 Decoy Oligodeoxynucleotides on Vascular Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo
Open Access
- 28 June 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 90 (12) , 1325-1332
- https://doi.org/10.1161/01.res.0000023200.19316.d5
Abstract
Excessive proliferation of vascular smooth muscle cells (VSMCs) and neointimal formation are critical steps in the pathogenesis of atherosclerosis and restenosis after percutaneous transluminal angioplasty. In this study, we investigated the hypothesis that the activator protein-1 (AP-1) plays an important role in neointimal formation after vascular injury. A circular dumbbell AP-1 decoy oligodeoxynucleotide (CDODN) was developed as a novel therapeutic strategy for restenosis after angioplasty. This CDODN was more stable than the conventional phosphorothioate linear decoy ODN (PSODN) and maintained structural integrity on exposure to exonuclease III or serum. Transfection with AP-1 decoy ODNs strongly inhibited VSMC proliferation and migration, as well as glucose- and serum-induced expression of PCNA and cyclin A genes. Administration of AP-1 decoy ODNs in vivo using the hemagglutinating virus of Japan (HVJ)-liposome method virtually abolished neointimal formation after balloon injury to the rat carotid artery. Compared with PSODN, CDODN was more effective in inhibiting the proliferation of VSMCs in vitro and neointimal formation in vivo. Our results collectively indicate that AP-1 activation is crucial for the mediation of VSMC proliferation in response to vascular injury. Moreover, the use of stable CDODN specific for AP-1 activity in combination with the highly effective HVJ-liposome method provides a novel potential therapeutic strategy for the prevention of restenosis after angioplasty in humans.Keywords
This publication has 18 references indexed in Scilit:
- Reactive Oxygen and NF-κB in VEGF-Induced Migration of Human Vascular Smooth Muscle CellsBiochemical and Biophysical Research Communications, 2001
- Potent Growth Inhibition of Leukemic Cells by Novel Ribbon-type Antisense Oligonucleotides to c-myb1Journal of Biological Chemistry, 2000
- Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation.Journal of Clinical Investigation, 1998
- Role of AP-1 Complex in Angiotensin II-Mediated Transforming Growth Factor-β Expression and Growth of Smooth Muscle Cells: Using Decoy Approach against AP-1 Binding SiteBiochemical and Biophysical Research Communications, 1998
- In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarctionNature Medicine, 1997
- Down-regulation of the Cyclin A Promoter by Transforming Growth Factor-β1 Is Associated with a Reduction in Phosphorylated Activating Transcription Factor-1 and Cyclic AMP-responsive Element-binding ProteinJournal of Biological Chemistry, 1997
- Enhanced Expression of Platelet-Derived Growth Factor-β Receptor by High Glucose Involvement of Platelet-Derived Growth Factor in Diabetic AngiopathyDiabetes, 1996
- Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.Journal of Clinical Investigation, 1994
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Regulation of Gene Expression with Double-Stranded Phosphorothioate OligonucleotidesScience, 1990